Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Baricitinib

FDA-approved product (tablet, oral), marketed as Baricitinib, Olumiant.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Baricitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Rheumatoid arthritis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Janus-associated kinase (jak) inhibitors
FDA pharmacologic class
Janus Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Baricitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Baricitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Baricitinib and Probenecid in Healthy Participants

    NCT01937026 · start 2013-09

    Registered record
    Registry ID
    NCT01937026
    Conditions
    Healthy Volunteers
    Interventions
    Baricitinib; Probenecid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-09
    Completion
    2013-11
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionBaricitinib; Probenecid
    PhasePhase 1
    Registry statusCompleted

  • A Study of Baricitinib and Rifampicin in Healthy Participants

    NCT01910311 · start 2013-08

    Registered record
    Registry ID
    NCT01910311
    Conditions
    Healthy Volunteers
    Interventions
    Baricitinib; Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-08
    Completion
    2013-10
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionBaricitinib; Rifampicin
    PhasePhase 1
    Registry statusCompleted

  • A Study in Moderate to Severe Rheumatoid Arthritis

    NCT01710358 · start 2012-10

    Registered record
    Registry ID
    NCT01710358
    Conditions
    Rheumatoid Arthritis
    Interventions
    Adalimumab; Baricitinib; Methotrexate; Adalimumab Placebo; Baricitinib Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-10
    Completion
    2015-09
    Enrolment
    1,307

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionAdalimumab; Baricitinib; Methotrexate; Adalimumab Placebo +1 more
    PhasePhase 3
    Registry statusCompleted

  • A Study of LY3009104 in Healthy Participants

    NCT01536951 · start 2012-02

    Registered record
    Registry ID
    NCT01536951
    Conditions
    Healthy Participants
    Interventions
    LY3009104; Placebo; moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-02
    Completion
    2013-05
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionLY3009104; Placebo; moxifloxacin
    PhasePhase 1
    Registry statusCompleted

  • Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects

    NCT01299285 · start 2011-02

    Registered record
    Registry ID
    NCT01299285
    Conditions
    Healthy Volunteers
    Interventions
    LY3009104
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-02
    Completion
    2011-03
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionLY3009104
    PhasePhase 1
    Registry statusCompleted